ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CBIO Catalyst Biosciences Inc

0.5113
0.00 (0.00%)
Mar 27 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.53
Ask Price 0.5796
News -
Day High

Low
0.19

52 Week Range

High
0.74

Day Low
Company Name Stock Ticker Symbol Market Type
Catalyst Biosciences Inc CBIO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.5113 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.5113 0.5113
Trades Volume Avg Volume 52 Week Range
0 0 - 0.19 - 0.74
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.5113 USD

Catalyst Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
660.37M 37.76M - 794k -8.24M -0.22 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Catalyst Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CBIO Message Board. Create One! See More Posts on CBIO Message Board See More Message Board Posts

Historical CBIO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.500.5880.320.4663444343,7550.01132.26%
1 Year0.200.740.190.3904581441,1740.3113155.65%
3 Years5.135.46850.18871.251,164,271-4.62-90.03%
5 Years8.2711.970.18872.14781,894-7.76-93.82%

Catalyst Biosciences Description

Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.

Your Recent History

Delayed Upgrade Clock